You are here

  • Home
  • Archive
  • Volume 12, Issue 1
  • Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146

Article metrics

Article menu

Download PDFPDF

Clinical/translational cancer immunotherapy
Original research
Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146

 

Online download statistics by month:

Online download statistics by month: January 2024 to August 2025

AbstractFullPdf
Jan 2024746749250
Feb 2024282286123
Mar 2024184184115
Apr 202415815866
May 202413613871
Jun 20249610064
Jul 202410410446
Aug 2024868538
Sep 2024737346
Oct 202410510558
Nov 2024818237
Dec 2024969848
Jan 202511411865
Feb 2025727241
Mar 2025919162
Apr 202510010047
May 2025616146
Jun 2025595941
Jul 2025110
Aug 2025110
Total264626651264